What's new? Log in Free sign up

IDEAYA Biosciences (IDYA)

Company Profile

Company profile

Ticker

IDYA

Exchange

Website

www.ideayabio.com

CEO

Yujiro S. Hata

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Global Partner Acquisition Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

474268251

IDYA stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$51.50

Low target

$44.00

High target

$59.00

Truist Securities

Mizuho

Maintains

Outperform

$44.00

12 Sep 25

Latest filings (excl ownership)

View all

Quarterly report

4 Nov 25

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Entry into a Material Definitive Agreement

Registration of securities for employees

Quarterly report

5 Aug 25

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Departure of Directors or Certain Officers

Transcripts

Earnings call transcript

Latest ownership filings

View all

Beneficial ownership report (amended)

Beneficial ownership report (amended)

IDEAYA Biosciences, Inc.

Joshua Bleharski

Malcolm Garret Hampton

Scott W Morrison

CATHERINE J MACKEY

Financial summary

Financial statements Chart IDYA financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	299.73 mm	299.73 mm	299.73 mm	299.73 mm	299.73 mm	299.73 mm
Cash burn (monthly)	(no burn)	8.46 mm	(no burn)	17.41 mm	(no burn)	8.52 mm
Cash used (since last report)	n/a	20.43 mm	n/a	42.06 mm	n/a	20.59 mm
Cash remaining	n/a	279.30 mm	n/a	257.67 mm	n/a	279.14 mm
Runway (months of cash)	n/a	33.0	n/a	14.8	n/a	32.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

IDYA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	208	213	-2.3%
Opened positions	33	35	-5.7%
Closed positions	38	24	+58.3%
Increased positions	94	106	-11.3%
Reduced positions	54	46	+17.4%

13F shares	Current	Prev Q	Change
Total value	2.24 tn	2.75 tn	-18.5%
Total shares	99.15 mm	99.07 mm	+0.1%
Total puts	24.10 k	20.00 k	+20.5%
Total calls	39.60 k	69.00 k	-42.6%
Total put/call ratio	0.6	0.3	+110.0%

Largest owners	Shares	Value	Change
FMR	12.96 mm	$333.15 bn	+2.6%
BlackRock	8.38 mm	$215.29 bn	+9.1%
JHG Janus Henderson	5.86 mm	$150.61 bn	+13.5%
Vanguard	5.08 mm	$130.51 bn	+5.9%
FHI Federated Hermes	5.06 mm	$130.13 bn	-2.8%
T. Rowe Price	3.87 mm	$99.38 mm	-3.7%
STT State Street	3.32 mm	$85.35 bn	+0.1%
Logos Global Management	3.00 mm	$77.10 bn	+42.9%
Deerfield Management	2.74 mm	$70.32 bn	+5.5%
Capital Research Global Investors	2.57 mm	$65.94 bn	-0.0%

Largest transactions	Shares	Bought/sold	Change
Boxer Capital	0.00	-2.20 mm	EXIT
BVF	0.00	-1.41 mm	EXIT
MS Morgan Stanley	1.56 mm	+1.19 mm	+331.2%
Soleus Capital Management	0.00	-1.05 mm	EXIT
Logos Global Management	3.00 mm	+900.00 k	+42.9%
GS The Goldman Sachs Group, Inc.	1.76 mm	+888.95 k	+102.3%
Citadel Advisors	1.84 mm	+784.45 k	+74.5%
BlackRock	8.38 mm	+696.12 k	+9.1%
JHG Janus Henderson	5.86 mm	+695.26 k	+13.5%
Sofinnova Investments	1.07 mm	-680.37 k	-38.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IDYA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Jun 25	Rosen Terry J	Stock Option Common Stock	Grant	Acquire A	No	No	21.78	20,000	435.60 k	20,000
24 Jun 25	Catherine J Mackey	Stock Option Common Stock	Grant	Acquire A	No	No	21.78	20,000	435.60 k	20,000
24 Jun 25	Morrison Scott W	Stock Option Common Stock	Grant	Acquire A	No	No	21.78	20,000	435.60 k	20,000
24 Jun 25	Hampton Malcolm Garret	Stock Option Common Stock	Grant	Acquire A	No	No	21.78	20,000	435.60 k	20,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Ideaya Biosciences Completed Its Targeted Full Enrollment of 435 Patients In Phase 2/3 OptimUM-02 Trial of Darovasertib Combined With Pfizer's Crizotinib for HLA*A2-Negative Metastatic Uveal Melanoma; Median Progression-free Survival Data is Expected in Q1 2026

OptimUM-02 is a multi-arm, multi-stage, open-label Phase 2/3 trial with patients randomized to receive either the darovasertib and crizotinib combination or investigator's choice of treatment (pembrolizumab, ipilimumab +

IDEAYA Biosciences Submits FDA Application for First-in-Class KAT6/7 Dual Inhibitor IDE574, Targets Early 2026 Trials

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE574,

On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030

On December 4, 2025, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) ("GSK") communicated to IDEAYA Biosciences, Inc. (the "Company") its election to terminate the Collaboration, Option and License Agreement, dated

IDEAYA Biosciences Secures IND Clearance For IDE034 Bispecific B7H3 PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

Truist Securities Initiates Coverage On IDEAYA Biosciences with Buy Rating, Announces Price Target of $59

Press releases

From Benzinga Pro

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trialTopline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision oncology company, has received the clearance of an investigational

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.